adlitterio66339

Circa adlitterio66339

Questo autore non ha riempito alcun dettaglio.
Finora adlitterio66339 ha creato 727 post nel blog.

22 03, 2024

Albino Eccher et al., Pathology Laboratory Archives: Conservation Quality of Nucleic Acids and Proteins for NSCLC Molecular Testing

adlitterio663392024-04-10T12:56:50+02:00

19 03, 2024

Marco Capezzone et al., Identification of a Novel Non-V600E BRAF Mutation in Papillary Thyroid Cancer

adlitterio663392024-04-10T12:55:59+02:00

16 03, 2024

Melchior Linea et al., Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC

adlitterio663392024-04-10T14:12:12+02:00

13 03, 2024

Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare

adlitterio663392024-03-15T15:51:52+01:00

1 03, 2024

Diatech Pharmacogenetics contribuisce al progetto “umanizzazione delle cure di terapia intensiva”
Diatech Pharmacogenetics contribuisce al progetto “umanizzazione delle cure di terapia intensiva”

Notizie

Diatech Pharmacogenetics contribuisce al progetto “umanizzazione delle cure di terapia intensiva”

adlitterio663392024-03-01T16:57:08+01:00

1 03, 2024

Jesi Terapia Intensiva, i murales degli studenti scaldano il cuore del reparto

adlitterio663392025-01-29T11:48:22+01:00

27 02, 2024

Federica Di Maggio et al., A Novel DNA Variant in SMARCA4 Gene Found in a Patient Affected by Early Onset Colon Cancer

adlitterio663392024-04-10T14:18:42+02:00

20 02, 2024

Fabio Canino et al., Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

adlitterio663392024-04-10T14:30:59+02:00

20 02, 2024

Zahra Abrehdari-Tafreshi et al., The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients

adlitterio663392024-04-10T14:21:40+02:00

14 02, 2024

Lorenza Rimassa et al., Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

adlitterio663392024-04-10T14:35:43+02:00

Precedente 8910 Successivo